Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 10/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 9/20 | 0.41 |
| ▸ | TP53 | P04637 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2291629 | 0.95 | TRPA1 (0.43) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL16266115 | 0.95 | TRPA1 (0.42) | GAATRPA1MAPTTP53ABL1 | |
| SCHEMBL2289522 | 0.92 | TRPA1 (0.41) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2289507 | 0.92 | TRPA1 (0.41) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2292148 | 0.92 | TRPA1 (0.43) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2292118 | 0.91 | TRPA1 (0.41) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2293280 | 0.91 | GAA (0.47) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2289509 | 0.91 | GAA (0.45) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2287216 | 0.91 | TRPA1 (0.44) | GAATRPA1MAPTTP53SMN1; SMN2 | |
| SCHEMBL2291610 | 0.90 | GAA (0.43) | GAATRPA1MAPTTP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | claimed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | claimed |
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GESELLSCHAFT (DE) | 2011-08-11 | — | — | US | claimed |
| EP-2032571-B1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2014-12-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195991-A1 | 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS | GLP1R, SLC5A1, SLC5A2 | GAA 1202/4885TRPA1 1229/4885MAPT 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.